7238 related articles for article (PubMed ID: 3093425)
1. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.
Nakamura S; Nakata K; Kashimoto S; Yoshida H; Yamada M
Jpn J Cancer Res; 1986 Aug; 77(8):767-73. PubMed ID: 3093425
[TBL] [Abstract][Full Text] [Related]
2. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
Nakamura S; Kashimoto S; Kajikawa F; Nakata K
Cancer Res; 1991 Jan; 51(1):215-21. PubMed ID: 1899039
[TBL] [Abstract][Full Text] [Related]
3. Augmented antitumor effect of recombinant human interleukin-1 alpha by indomethacin.
Nakata K; Kashimoto S; Yoshida H; Oku T; Nakamura S
Cancer Res; 1988 Feb; 48(3):584-8. PubMed ID: 3257168
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
[TBL] [Abstract][Full Text] [Related]
8. [Effects of recombinant human interferon-alpha A/D on the growth of experimental tumors in mice].
Ootsu K; Kozai Y; Houkan T; Gotoh K; Matsutani E
Gan To Kagaku Ryoho; 1987 Aug; 14(8):2502-8. PubMed ID: 3304169
[TBL] [Abstract][Full Text] [Related]
9. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
Asher A; Mulé JJ; Reichert CM; Shiloni E; Rosenberg SA
J Immunol; 1987 Feb; 138(3):963-74. PubMed ID: 3805720
[TBL] [Abstract][Full Text] [Related]
10. [Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
Nakata K; Yoshida H; Kashimoto S; Sohmura Y; Nakamura S; Taguchi T
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3186-93. PubMed ID: 3096217
[TBL] [Abstract][Full Text] [Related]
11. [Antitumor effect of human recombinant interferon-alpha A/D in mice(I): Comparison between systemic and lesional treatment of meth-A sarcoma in BALB/c mice].
Nanjo M; Yoshie O; Aso H; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):505-9. PubMed ID: 4004283
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
13. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.
Berman RM; Suzuki T; Tahara H; Robbins PD; Narula SK; Lotze MT
J Immunol; 1996 Jul; 157(1):231-8. PubMed ID: 8683120
[TBL] [Abstract][Full Text] [Related]
14. Effect of recombinant interleukin-1 alpha, recombinant interleukin-2, recombinant interferon-beta, and recombinant tumor necrosis factor on subcutaneously implanted adenocarcinoma 755 and Lewis lung carcinoma.
Iigo M; Nishikata K; Hoshi A
J Biol Response Mod; 1990 Aug; 9(4):426-30. PubMed ID: 2395006
[TBL] [Abstract][Full Text] [Related]
15. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
16. Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors.
Kataoka T; Matsuura N; Oh-hashi F; Suhara Y
Cancer Res; 1985 Aug; 45(8):3548-53. PubMed ID: 2410097
[TBL] [Abstract][Full Text] [Related]
17. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
18. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
Haranaka K; Sakurai A; Satomi N
J Biol Response Mod; 1987 Aug; 6(4):379-91. PubMed ID: 3625230
[TBL] [Abstract][Full Text] [Related]
20. [Potentiation of chemotherapeutic activity by a Chinese herb medicine juzen-taiho-toh].
Komiyama K; Hirokawa Y; Zhibo Y; Umezawa I; Hata T
Gan To Kagaku Ryoho; 1988 May; 15(5):1715-9. PubMed ID: 3130806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
